Fierce Biotech: Eisai to drop up to $15M on C2N Diagnostics to boost the reach of Alzheimer's disease blood tests

Mar 7

Written by Joni Henderson

The Clinical Trial Vanguard: C2N Diagnostics partners with Mediford for Precivity™ Alzheimer’s Blood Test Expansion in Japan

Fierce Biotech: Study shows a front-line Alzheimer’s blood test could be as accurate as spinal fluid exams